-
Product Insights
Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Squamous Non-Small Cell Lung Cancer - Drugs In Development, 2023’, provides an overview of the Squamous Non-Small Cell Lung Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Izuforant in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Izuforant in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Izuforant in Atopic Dermatitis (Atopic Eczema)Drug Details:Izuforant is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPYK-04 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPYK-04 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SPYK-04 in Non-Small Cell Lung Cancer Drug Details:SPYK-04 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLC-0111 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLC-0111 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SLC-0111 in Pancreatic Ductal AdenocarcinomaDrug Details:SLC-0111 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olezarsen Sodium in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olezarsen Sodium in Atherosclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olezarsen sodium in Atherosclerosis Drug Details: AKCEA-APOCIIILRx is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Safimaltib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Safimaltib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Safimaltib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XZB-0004 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XZB-0004 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XZB-0004 in Non-Small Cell Lung Cancer Drug Details: SLC-391 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XZB-0004 in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XZB-0004 in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XZB-0004 in Squamous Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XZB-0004 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XZB-0004 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XZB-0004 in Solid Tumor Drug Details: SLC-391 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XZB-0004 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XZB-0004 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XZB-0004 in Acute Myelocytic Leukemia (AML,...